Precision BioSciences, Inc.
NASDAQ:DTILBiotechnology
Healthcare
$6.91 +1.69%
+$0.11 today
- Market cap
- $193.04M
- Beta
- 1.28
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$3.47
52W Low $3.53High $8.82
Volume 0.27M
Average 0.31M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$65.84M
FY 2025 · Annual
Investing Cash Flow
-$634,000.00
FY 2025 · Annual
Financing Cash Flow
$95.16M
FY 2025 · Annual
+88.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.6M) | (111.64M) | (61.32M) | 7.17M | (45.72M) |
| Depreciation & Amortization | 10.2M | 9M | 8.26M | 4.58M | 2.75M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.51M | 19.2M | 14.04M | 12.6M | 10.19M |
| Change in Working Capital | 19.58M | 24.11M | (41.49M) | (54M) | (24.71M) |
| Accounts Receivables | 9.51M | (232K) | (181K) | 10.42M | 229K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 867K | 153K | 1.51M | (2.1M) | (737K) |
| Other Working Capital | 9.21M | 24.19M | (42.81M) | (62.33M) | (24.2M) |
| Other Non-Cash Items | (26.55M) | 13.57M | (3.6M) | (28.79M) | (8.35M) |
| Operating Cash Flow | (10.85M) | (45.75M) | (84.11M) | (58.45M) | (65.84M) |
| Capital Expenditures | (5.8M) | (3.32M) | (2.28M) | (250K) | (85K) |
| Acquisitions (Net) | 0 | 0 | 8M | 60K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (750K) | 0 | 107K | (25K) | (549K) |
| Investing Cash Flow | (5.8M) | (3.32M) | 5.83M | (215K) | (634K) |
| Debt Repayment | 2.47M | 19.81M | 0 | (37K) | 0 |
| Common Stock Issued | 60.48M | 74.35M | 4.99M | 50.24M | 95.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.57M | 835K | 401K | 249K | 0 |
| Financing Cash Flow | 70.52M | 94.99M | 5.39M | 50.45M | 95.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 53.87M | 45.91M | (72.9M) | (8.21M) | 28.69M |
| Free Cash Flow | (16.66M) | (49.07M) | (86.39M) | (58.7M) | (65.93M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$45.7M
+ D&A$2.8M
+ Stock-Based Comp$10.2M
+ Deferred Tax$0
- Working Capital-$24.7M
- Other Non-Cash-$8.3M
= Operating Cash Flow-$65.8M
- Capex-$85.0K
= Free Cash Flow-$65.9M
Analysis
FY2025 free cash flow is -$65.9M. FCF conversion is 144.2% of net income. Operating cash flow was -$65.8M, with capex of -$85.0K. The largest bridge item is Working Capital at -$24.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 424B5 | 424B5 filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| FWP | FWP filing | Nov 5, 2026 |
Does DTIL generate free cash flow?
Precision BioSciences, Inc. (DTIL) generated -$65.93M of free cash flow in fiscal 2025.
How much operating cash flow does DTIL produce?
Operating cash flow was -$65.84M, before capital expenditures of $85,000.00.
Continue the stock analysis
Jump to another research area for this company.